Table 4.

Summary of identified clinical studies using in vivo dosimetry in pelvic brachytherapy

Year Authors (citation)	Type of dosemeter	Clinical application	Location of detector	Differences between calculated and measured doses
2021 Hayashi et al. 58	Optically stimulated luminescence	HDR cervix	Rectal probe	Mean +3.9 (±12.7% SD)
2020 Mason et al. 63	MOSFET	HDR prostate	Brachytherapy needle in prostate	Mean +5.2% (range -17.3% to +7.4%)
2020 Poder et al. 64	MOSkin (MOSFET)	HDR prostate	Rectal probe	Mean 0.3% (±11.6% SD)
2020 Jamalludin et al. 59	MOSkin (MOSFET) and PTW 9112 semiconductor	HDR cervix	Rectal probe	MOSkin: Mean −3.2% (±10.1% SD); PTW 9112: Mean −15.5% (±9.7% SD)
2018 Johansen et al. 61	Optical fibre	HDR prostate	Brachytherapy needle in prostate	Mean -4.7% (range -17 to +12%)
2018 Belley et al. 60	Optical fibre / thermoluminescence	HDR vagina	Lateral surface of vaginal cylinder	63% of measurements were within 5% of TPS; 26% within 5–10%; 11% within 10–20%
2017 Carrara et al. 65	MOSkin (MOSFET)	HDR vagina	Rectal probe	Mean +2.2% (±6.9% SD)
2017 Wagner et al. 66	Alanine/electron spin resonance	HDR prostate	Urinary catheter	Mean -2.4 Gy (range -7.9 to +0.2 Gy)
2017 Van Gellekom et al. 67	MOSFET	HDR vagina	Vaginal applicator needle	Mean +3% (±14% SD)
2016 Carrara et al. 68	MOSkin (MOSFET)	HDR prostate	Rectal probe	Mean +6.7% (range ±5.1% SD)
2016 Mason et al. 69	MOSFET	HDR prostate	Brachytherapy needle in prostate	Mean -6.4% (range +5.1 to 15.2%)
2014 Zaman et al. 70	Semiconductor diode	HDR cervix	Rectal probe	Range -8.5% to +41.2%
2013 Sharma et al.(93)	Optically stimulated luminescence	HDR cervix	Rectal retractor	Range -14.9% to +13.7%
2012 Allahverdi et al. 71	Semiconductor diode	HDR cervix	Rectal probe	Mean 6.5% (range -22 to +39%)
2011 Suchowerska et al.(94)	Optical fibre	HDR prostate	Urinary catheter	≤9%

HDR, high dose rate; MOSFET, metal-oxide-semiconductor field-effect transistor